Cue Biopharma Initiates Patient Dosing in Phase 1 Study of CUE-101 in Combination with KEYTRUDA® (pembrolizumab) as First-line Treatment for HPV+ Recurrent/Metastatic Head and Neck Cancer

Go back to Cue Biopharma Initiates Patient Dosing in Phase 1 Study of CUE-101 in Combination with KEYTRUDA® (pembrolizumab) as First-line Treatment for HPV+ Recurrent/Metastatic Head and Neck Cancer
(NASDAQ: CUE) Delayed: 10.90 -0.36 (3.2%)
Previous Close $11.26    52 Week High
Open $11.26    52 Week Low
Day High $11.39    P/E N/A 
Day Low $10.69    EPS
Volume 147,668